GlassScriptPhysician profile
David P Dean
NPI 1790744811
$7,644.34
in general payments reported to CMS, 2019-2025
31 companies · $662 in 2025
The $662 reported for 2025 was less than what a typical Thoracic Surgery (Cardiothoracic Vascular Surgery) provider received nationally (typical 2025 total: $796).
See the full distribution for Thoracic Surgery (Cardiothoracic Vascular Surgery)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,459 · 2020: $173 · 2021: $726 · 2022: $1,123 · 2023: $1,032 · 2024: $2,470 · 2025: $662.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,843 · Travel and Lodging: $1,320.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,843.49 |
| Travel and Lodging | $1,319.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mimedx Group, INC. | $1,649.47 | 2024-2025 | |
| Smith+Nephew, INC. | $1,567.30 | 2019-2025 | Collagenase Santyl, Renasys Go V2 Home, Allevyn Heel 10.5cm X 13.5cm Ctn 5 |
| Paratek Pharmaceuticals, INC. | $693.13 | 2019-2025 | Nuzyra |
| Integra Lifesciences Corporation | $602.47 | 2019-2021 | |
| Kci USA, INC. | $480.13 | 2019-2023 | Activ.A.C., Promogran Prisma, Activ.A.C. Ion Progress |
| Biotissue Holdings INC. | $385.30 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $375.84 | 2019-2022 | |
| Kerecis Limited | $253.56 | 2019-2025 | Kerecis Surgiclose, Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen |
| Organogenesis INC. | $205.88 | 2021-2022 | |
| Abbvie INC. | $180.39 | 2021-2025 | Dalvance |
| Solventum Corporation | $173.73 | 2024-2025 | V.A.C.Ulta, V.A.C. Veraflo Cleanse Choice, Prevena |
| Averitas Pharma INC. | $129.85 | 2024 | Qutenza |
| Shionogi INC | $126.73 | 2023-2024 | Fetroja |
| Melinta Therapeutics, LLC | $123.38 | 2019 | |
| Misonix INC | $119.69 | 2019 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $112.00 | 2019 | |
| Hollister Incorporated | $89.03 | 2025 | New Image |
| Amniox Medical, INC. | $74.82 | 2019 | |
| Merck Sharp & Dohme LLC | $64.51 | 2019 | |
| Coloplast Corp | $30.90 | 2024 | |
| Cashflow Solutions, LLC | $30.12 | 2022-2024 | Lympha Press Optimal Plus(US) Bt, Pcd-51 731a (US) - White, Pcd-52 737a (US) White |
| Tei Medical INC. | $27.80 | 2019 | |
| Tactile Systems Technology INC | $25.41 | 2023 | Entre Plus, Flexitouch Plus |
| Advanced Oxygen Therapy INC. | $19.65 | 2025 | Topical Oxygen Chamber For Extremities |
| Nestle Healthcare Nutrition INC. | $17.58 | 2022 | |
| Urgo Medical North America, LLC | $16.77 | 2024 | Urgoclean Ag |
| Nabriva Therapeutics, Plc | $15.76 | 2020 | |
| Nevro Corp. | $15.56 | 2024 | Senza |
| Shire North American Group INC | $15.53 | 2019 | |
| Osiris Therapeutics INC. | $11.09 | 2019 | |
| Aroa Biosurgery Incorporated | $10.96 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Dean listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.